Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Rutgeerts, Paul; J. Sandborn, William; G. Feagan, Brian; Reinisch, Walter; Olson, Allan; Johanns, Jewel; Travers, Suzanne; Rachmilewitz, Daniel; B. Hanauer, Stephen; R. Lichtenstein, Gary; J.S. de Villiers, Willem; H. Present, Daniel; E. Sands, Bruce; Colombel, Jean‐Frédéric

doi:10.1056/nejmoa050516

Public

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Published in New England Journal of Medicine • Dec 7, 2005

Authors:

Paul Rutgeerts

William J. Sandborn

Brian G. Feagan

Abstract

BACKGROUND: Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis. METHODS: Two randomized, double-blind, placebo-controlled studies--the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ...

Subject

Infliximab

Medicine

Ulcerative colitis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!